Sica, A.; Sagnelli, C.; Casale, B.; Svanera, G.; Creta, M.; Calogero, A.; Franco, R.; Sagnelli, E.; Ronchi, A. How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas ALK+ Therapy: A Case Report. Healthcare2021, 9, 135.
Sica, A.; Sagnelli, C.; Casale, B.; Svanera, G.; Creta, M.; Calogero, A.; Franco, R.; Sagnelli, E.; Ronchi, A. How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas ALK+ Therapy: A Case Report. Healthcare 2021, 9, 135.
Sica, A.; Sagnelli, C.; Casale, B.; Svanera, G.; Creta, M.; Calogero, A.; Franco, R.; Sagnelli, E.; Ronchi, A. How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas ALK+ Therapy: A Case Report. Healthcare2021, 9, 135.
Sica, A.; Sagnelli, C.; Casale, B.; Svanera, G.; Creta, M.; Calogero, A.; Franco, R.; Sagnelli, E.; Ronchi, A. How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas ALK+ Therapy: A Case Report. Healthcare 2021, 9, 135.
Abstract
Background: The t (2; 5) chromosomal rearrangement and resulting nucleophosmin (NPM1) -ALK fusion was first observed in 1994 in anaplastic large cell lymphoma (ALCL), a T-cell lymphoma responsive to cyclophosphamide, abriblastine, vincristine and prednisone in approximately 80% of cases; refractory cases usually respond favorably to brentuximab-vedotin. These treatments are regarded as a bridge to allogeneic hematopoietic stem cell transplantation (allo-SCT). Nowadays, transplant procedures and monitoring of chemotherapy patients proceed very slowly because the SARS-CoV-2 pandemic has heavily clogged the hospitals in all countries. Results: A 40-year-old Caucasian woman was first seen at our clinical center in June 2020. She had ALCL ALK +, a history of failure to two previous therapeutic lines and was in complete remission after 12 courses of Brentuximab, still pending allo-SCT after two failed donor selection. Facing of a new therapeutic failure, we requested the Italian drug regulatory agency, and obtained the authorization, to administer 250 mg twice a day of Crizotinib, a drug incomprehensibly not registered for ALCL ALK +. Conclusions: The response to Crizotinib was optimal, since no adverse event occurred, and CT-PET persisted negative; this drug has proved to be a valid bridge to allo-SCT
Keywords
Crizotinib; Anaplastic Large Cell Lymphomas ALK+; bridge therapy in NHL ALK+; ALK+ patients; anticancer therapy
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.